Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» AbbVie
AbbVie
In label expansion bid, AbbVie and Roche's Venclexta falls short in multiple myeloma subset
In label expansion bid, AbbVie and Roche's Venclexta falls short in multiple myeloma subset
Fierce Pharma
AbbVie
Roche
Venclexta
Multiple Myeloma
Flag link:
AbbVie Terminates Collaboration and License Agreement with Caribou Biosciences
AbbVie Terminates Collaboration and License Agreement with Caribou Biosciences
Best Stocks
AbbVie
Caribou Biosciences
CRISPR
Flag link:
AbbVie Ends I-Mab Partnership for CD47 Antibody Compounds, Products
AbbVie Ends I-Mab Partnership for CD47 Antibody Compounds, Products
BioSpace
AbbVie
I-Mab Biopharma
Flag link:
Third Time Might Be a Charm for Alvotech as FDA Accepts BLA for Humira Biosimilar
Third Time Might Be a Charm for Alvotech as FDA Accepts BLA for Humira Biosimilar
BioSpace
Alvotech
FDA
biosimilars
AVT02
AbbVie
Humira
Flag link:
Revance rolls out a price drop for Daxxify as it tries to challenge AbbVie's Botox
Revance rolls out a price drop for Daxxify as it tries to challenge AbbVie's Botox
Fierce Pharma
Revance Therapeutics
Daxxify
AbbVie
Botox
drug pricing
Flag link:
With trial win, AbbVie cues up Botox for another cosmetic indication
With trial win, AbbVie cues up Botox for another cosmetic indication
Fierce Pharma
AbbVie
Botox
aesthetics
platysma prominence
Flag link:
AbbVie Passes on License Option for Harpoon’s TriTAC Multiple Myeloma Program
AbbVie Passes on License Option for Harpoon’s TriTAC Multiple Myeloma Program
BioSpace
AbbVie
Harpoon Therapeutics
HPN217
Multiple Myeloma
Flag link:
AbbVie’s Skyrizi Outperforms J&J’s Stelara in Late-Stage Crohn’s Disease Trial
AbbVie’s Skyrizi Outperforms J&J’s Stelara in Late-Stage Crohn’s Disease Trial
BioSpace
AbbVie
Skyrizi
JNJ
Stelara
Crohn's Disease
clinical trials
Flag link:
GSK spends big on new RSV vax commercials, but it's an AbbVie clean sweep as August's top pharma drug ad spender
GSK spends big on new RSV vax commercials, but it's an AbbVie clean sweep as August's top pharma drug ad spender
Fierce Pharma
AbbVie
GSK
DTC advertising
pharma marketing
Flag link:
AbbVie’s Humira to Take Hit from Biosimilars, Next-Gen Therapies: Report
AbbVie’s Humira to Take Hit from Biosimilars, Next-Gen Therapies: Report
BioSpace
AbbVie
Humira
biosimilars
Crohn's Disease
Flag link:
AbbVie in line for hefty payout after Takeda breached supply contract on Lupron
AbbVie in line for hefty payout after Takeda breached supply contract on Lupron
Fierce Pharma
AbbVie
Takeda
legal
Lupron
Flag link:
Biden administration lists 10 drugs for Medicare price negotiation
Biden administration lists 10 drugs for Medicare price negotiation
Medical Marketing and Media
Medicare
HHS
Pfizer
Bristol Myers Squibb
Eli Lilly
Boehringer Ingelheim
AstraZeneca
AbbVie
Novo Nordisk
JNJ
drug pricing
Flag link:
AbbVie Removes Two Early-Stage Cancer Assets from Pipeline
AbbVie Removes Two Early-Stage Cancer Assets from Pipeline
BioSpace
AbbVie
antibody-drug conjugate
cancer
Flag link:
Why AbbVie’s former president has high hopes for this Flagship-backed biotech
Why AbbVie’s former president has high hopes for this Flagship-backed biotech
Pharma Voice
Tessara Therapeutics
gene writing
AbbVie
Flagship Pioneering
Michael Severino
Flag link:
Amgen's hyped Humira biosimilar fritters away its exclusivity advantage
Amgen's hyped Humira biosimilar fritters away its exclusivity advantage
Fierce Pharma
Amgen
AbbVie
biosimilars
Humira
Flag link:
Despite big Q2 declines for Humira and Imbruvica, AbbVie still boosts earnings guidance
Despite big Q2 declines for Humira and Imbruvica, AbbVie still boosts earnings guidance
Fierce Pharma
AbbVie
earnings
Humira
biosimilars
Imbruvica
Flag link:
Biosimilar makers split strategies in bid to take on top-selling Humira
Biosimilar makers split strategies in bid to take on top-selling Humira
BioPharma Dive
biosimilars
Humira
AbbVie
rebates
drug pricing
Amgen
Celltrion
Novartis
Boehringer Ingelheim
Biocon
Fresenius
Sandoz
Organon
Coherus
Flag link:
AbbVie's Skyrizi delivers head-to-head win versus Amgen's Otezla in psoriasis
AbbVie's Skyrizi delivers head-to-head win versus Amgen's Otezla in psoriasis
Fierce Pharma
AbbVie
Skyrizi
Amgen
Otezla
Boehringer Ingelheim
psoriasis
Flag link:
Teva expands Alvotech collab with 2 more biosims, increased manufacturing oversight and a $40M investment
Teva expands Alvotech collab with 2 more biosims, increased manufacturing oversight and a $40M investment
Fierce Pharma
Teva Pharmaceutical
Alvotech
biosimilars
Humira
AbbVie
drug manufacturing
Flag link:
Companies to Watch: 12 Late-Stage Contenders in Neurodegenerative Disease
Companies to Watch: 12 Late-Stage Contenders in Neurodegenerative Disease
BioSpace
neurodegenerative disease
Alzheimer's disease
Axsome Therapeutics
Eli Lilly
Anavex
TauRx
AB Science
ALS
BrainStorm Cell Therapeutics
Seelos Therapeutics
Parkinson's Disease
AbbVie
Mitsubishi Tanabe Pharma
Annovis
Huntington's disease
Prilenia Therapeutics
Neurocrine
Flag link:
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »